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The management of Ventilator Associated Pneumonia (VAP) presents many difficulties because of the heterogeneity
of the disease; the way the immunocompromised host and the aggressive ICU environment interact is only partially
discovered, the available biomarkers for diagnosis are not sufficient to ensure prompt differentiation between sick
patients and patients at risk, the microbiological cultures require invasive techniques and time consuming methods.
A translational medicine and bio-informatics approach can enable the identification of the main players of pathology,
which may represent novel therapeutic targets or biomarker candidates. Analysis of proteome i.e. allows to individuate
proteins that act as biomarkers, for patient-centered research strategies. Similarly, the genomic approach has proved
useful to individuate those patients who are prone to develop VAP, and, in the future, we could be able to
immunomodulate their responses to save them from nosocomial infections.
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VAP (Ventilator Associated Pneumonia) is classically
defined as a hospital-acquired pneumonia developing
48 hours or later after the beginning of mechanical
ventilation.
Since VAP diagnosis founded on radiographic findings
of pneumonia, which have intrinsic variability in tech-
nique, interpretation, and reporting, and on clinical signs
and symptoms- that are subjective- in 2011 a Working
Group of the CDC (Centers for Disease Control and
Prevention) proposed a new approach to surveillance for
Ventilator-Associated Events (VAE). According to the
new CDC definition algorithm, VAP is an Infection-
related Ventilator-Associated Complication (IVAC) oc-
curring after 3 days of mechanical ventilation and 2 days
before or after the onset of worsening oxygenation, if
purulent respiratory secretions with positive cultures or
objective signs of respiratory infection have been found
[1]. The need for a new and efficacious operative defin-
ition is comprehensible, since VAP remains one of the
commonest nosocomial infections in the intensive care
unit (ICU), affecting 8% to 28% of patients receiving* Correspondence: xiangdong.wang@clintransmed.org
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reproduction in any medium, provided the origmechanical ventilation [2]. Patients who develop a VAP
have significantly more ventilator days, hospital days,
and antibiotic days and higher hospital mortality than
patients who have not this condition. The hazard for
mortality is calculated about 7.2 (95% CI 5.1 - 10.3) for
VAP identified by prospective surveillance [3]. Thanks to
the generic improvements in critical care [4], mortality
following VAP decreased slightly over time. Even if the
“ventilator bundle” (4 items to prevent respiratory com-
plications: stress ulcer prophylaxis, deep venous throm-
bosis prophylaxis, head-of-bed elevation, daily sedation
vacation with weaning assessment), introduced by the
Institute for Health Care Improvement, has been par-
tially accepted, there is little evidence of its efficacy up
to now [5] and no specific intervention has been yet in-
dividuated to eradicate VAP. Over the past decade, the
accuracy of initial antibiotic treatment has been manifest
as one of the most consistent prognostic factor: early ag-
gressive therapy with adequate broad-spectrum regimens
against the likely pathogens is associated with lower
mortality rates and shorter length of hospital stay (LOS).
Patients receiving inadequate antibiotic therapy com-
pared with patients receiving adequate antibiotic therapy
reported a significantly longer hospital LOS: this was
calculated as plus 16.4 days (p = 0.009) for VAP [6].
There is general agreement that the causative agentis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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order to achieve long-lasting remission but prompt diag-
nosis and individuation of pathogens are still difficult.
Diagnostic methods with good sensitivity already exist
for VAP: they are the simple clinical criteria, but a bio-
marker with high specificity it is needed to guide the
clinician towards the sources of infection: increasing the
specificity of any screening test, the fewer false positive
would reduce the cost of antibiotics and invasive diag-
nostic strategies.
While its is clear the importance of a rapid causative
diagnosis, it remains unknown why some intubated pa-
tients remain infection free while other develop VAP
and other tracheobronchitis [7]. Ventilator-associated
tracheobronchitis (VAT) is very common in intubated
critically ill patients. This infection represents an inter-
mediate process between colonization of lower respiratory
tract and VAP. VAT is characterized by increased purulent
sputum production and lower respiratory tract inflamma-
tion resulting in difficult weaning and prolonged duration
of mechanical ventilation.
This area of controversy about the interaction between
the patient and his/her intensive care environment is ex-
tremely relevant, since the rapid individuation of subject
prone to infection should involve the aggressive treat-
ment while patients who have mild and indolent disease
need to be identified but not over treated. The role of
the underlying disease should be considered as domin-
ant and the primary endpoint in VAP management
should ideally be prevention. Areas timely for developing
research are strategy for VAP prevention, individuation
of biomarkers for early diagnosis and subgroups identifi-
cation, methods to develop and validate multi-drug resist-
ant pathogens detection on bronchoalveolar lavage (BAL)
or serum. We will expose the relevant result of recent clin-
ical translational works that aim to identify novel pathways
in VAP diagnosis and treatment.
Biomarkers for VAP diagnosis
As already said, clinical criteria for VAP diagnosis
present high sensibility but low specificity. Comorbid-
ities and other concomitant conditions as leukocytosis
may influence the evaluation of clinical data; fever in ICU
patients is extremely common and radiologic criteria is
often misleading. The Clinical Pulmonary Infection Score
(CPIS) takes into account some easily available parame-
ters: fever, leukocytosis, tracheal aspirates, oxygenation,
radiographic infiltrates, and may increase the specificity
of diagnosis when the sum of individual scores is higher
than 6. The initial data, published by Plugin et al. [8]
were not confirmed later in larger studies and, to increase
the CPIS specificity, the semi-quantitative cultures of tra-
cheal aspirates with Gram stain was introduced, still with
limited efficacy [9]. The weak point of CPIS is probablythe inter-individual variability, since a subjective evalu-
ation is required when we are judging the quality of tra-
cheal secretion (purulent/not purulent) and the presence
of infiltrate at chest ray.
Since clinical criteria are not specific enough, the need
for a simple clinical tool for the diagnosis of VAP is evi-
dent. A perfect biomarker (not expensive, not invasive,
which helps to avoid excess antibiotic use and assist in
the conduct of clinical research) is still lacking, but vari-
ous biological elements have been proposed, among
which Procalcitonin, Pentraxin3, and Soluble Triggering
Expressed on Myeloid Cells Type 1 are the most cited in
the literature.
Procalcitonin (PTC) is a pro-hormone, precursor of
Calcitonin. PTC is synthesised in virtually all organs and
in macrophages in response to pro-inflammatory stimuli,
particularly stimuli of bacterial origin. In a metanalysis
of 7 studies (373 patients, 434 episodes), Sotillo- Diaz
et al. [10] found that high plasma PCT levels were asso-
ciated to an increased risk of suffering ventilator-
associated pneumonia (OR: 8.39; 95% CI: 5.4-12.6).
Sensitivity and specificity were 76% (69–82) and 79%
respectively. Even if these values are fairly acceptable, we
should also consider that the CPIS score in selected popu-
lation (i.e. brain injury) [11] scores even better: 97% sensi-
tivity and 100% specificity and question the role of PCT as
unique screening test for VAP early diagnosis [12].
The diagnosis of VAP is not the only field of applica-
tion of PTC: it could be used for prognosis and to follow
antibiotic therapy. Using the combination of PCT plus
CPIS may be more powerful than PTC by itself: Su et al.
[13] in 2012 demonstrated that procalcitonin levels plus
the CPIS score was reliable for prognostic assessment
(28-day survival), in sepsis patient with VAP.
Assuming the patients meet the clinical criteria for
VAP, the PTC level could guide the duration of anti-
biotic therapy, allowing a safe individualised strategy for
VAP. Pugh et al. [14] reviewed three RCTs which investi-
gated strategies to reduce antibiotic exposure on the
basis of procalcitonin: the experimental strategy advo-
cated discontinuing antibiotic therapy when the serum
PTC level was below a cut-off value (0,5 or 0.25 μg/L,
depending on the investigators) or fell to less than 20%
of the level on Day 0. Duration of antibiotic therapy was
significantly shorter in patients treated according to
PTC-guided strategy than for patients allocated to stand-
ard therapy (durations of therapy for the procalcitonin
groups 9.2 days versus 12.1 days).
Taking the data all together, PTC looks useful but not
unequivocal as a biomarker for VAP diagnosis. The ex-
planation could be that PTC is a part of pro-inflammatory
response of the immune system and it could be seen as an
assistant to host, in recognition of invasion by bacteria,
discriminating viral from bacterial infections. Nevertheless
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stand how PTC really “works” during VAP.
Pentatraxin 3 (PTX3) is a protein targeted to inflam-
mation and has been proposed as an alternative bio-
marker for VAP diagnosis. PTX3 is a member of the
long pentraxin subfamily while the C-reactive protein
(CRP) is the prototype of short pentraxin and has been
widely used, with limited diagnostic and prognostic spe-
cificity in infectious diseases.
PTX3 is released by mononuclear phagocytes, neutro-
phils, epithelial and endothelial cells in response to in-
flammatory signals; PTX3 recognizes microbial molecules,
activates the classical pathway of complement and facili-
tates recognition by macrophages and dendritic cells. Lin
et al. [15] performed the measurement of PTX3 and CRP
levels in plasma from 136 consecutive patients receiving
mechanical ventilation > 48 hours in a prospective single
centre study. PTX3 > 16.43 ng/ml showed specificity of
74.0% and sensitivity of 68.6%, not superior to CRP as a
biomarker to diagnose VAP. The authors admit some limi-
tations of this single centre study and propose a larger
trial, which at the moment is lacking. Nevertheless, PTX3
is not a specific marker for bacterial infection. Elevated
plasma PTX3 concentrations are seen in various inflam-
matory conditions, which can be concomitant to VAP
diagnosis, making PTX3 a marker not enough specific for
this complication.
Triggering receptor expressed on myeloid cells-1
(TREM) is a glycoprotein member of the immunoglobu-
lin superfamily. TREM expression is up-regulated in the
presence of extracellular bacteria and fungi and some in-
flammatory conditions. In response to infection, soluble
TREM-1 (sTREM-1) can then be measured in body
fluids, while sTREM-1 levels are not detectable at base-
line in normal individuals.
In Palazzo et al. paper, sTREM-1 levels did not dis-
criminate VAP when compared to quantitative cultures
of bronchoalveolar lavage (commonly used as the gold
standard) [16]. Using a cutoff value of 204 pg/mL for
BALF sTREM-1 levels resulted in sensitivity of 79% and
specificity of 23%.
In conclusion, up to now no biomarker has yet im-
proved our clinical capacity to diagnose VAP: biologic
markers have been suggested to improve recognition of
patients with true infection and facilitate decisions of
whether or not to treat. Unfortunately, neither PCT, PTX3
or sTREM-1 fulfill all expectations.
In the recent years, it is been recognized that the
multivariate model is more promising than a single
biomarker for risk assessment of disease. This multi-
biomarker approach has progressed by recent advances
in clinical proteomics. Proteomics is a branch of biotech-
nology concerned with applying the techniques of mo-
lecular biology, biochemistry, and genetics to analyzingthe structure, function, and interactions of the proteins
produced by the genes of a particular cell, tissue, or or-
ganism, with organizing the information in databases,
and with applications of the data (as in medicine or
biology) [17]. In 2008 Lu et al. published the first global
description of the BAL proteome from patients with
VAP: they identified 206 proteins, defining the global
proteome map of BAL. Four selected proteins (gelsolin,
serum amyloid P-component, vitamin D-binding protein
and pyruvate kinase) [18] were significantly higher in
BAL from patients with VAP (p < 0.05). Applying a mod-
ern proteomic approach Nguyen et al. [19] identified a
proteomic “signature” that discriminated VAP(+) from
VAP(−) patients in Acute Lung Injury patients: it is con-
stituted by three BAL proteins: S100A8, lactotransferrin
(LTF), and actinin 1 (ACTN1).
The proteomic approach needs computational analyses
to became really powerful and study the proteome dur-
ing VAP. This integrative methodology is a strategy to
differentiate clinically relevant subsets of patients.
Metabolomics is the quantitative analysis of a large
number of low molecular mass metabolite, substrates or
products in metabolic pathways. It’s important to note
that Rogers et al. recently published a metabolomic
study in critically ill patients [20]: they formed a metabo-
lomic network of 7 metabolites associated with death
(gamma-glutamylphenylalanine, gamma-glutamyltyrosine,
1-arachidonoylGPC(20:4), taurochenodeoxycholate, 3-(4-
hydroxyphenyl) lactate, sucrose, kynurenine). This net-
work achieved a 91% AUC predicting 28-day mortality.
Similar studies are still lacking in the field of VAP but
would be a very practical and interesting translational ap-
proach application.
Prompt identification of VAP caused by MDR bacteria
Once the clinical suspicion of VAP is consolidated, se-
lection of the appropriate antimicrobial therapy is the
most urgent and following step. Quantitative culture of
bronchoalveolar lavage (BAL) has the highest sensitivity
and specificity to diagnose VAP and differentiate true in-
fection from colonisation or inflammation. The CDC
recommends that quantitative cultures be performed on
these specimens, using ≥ 104 CFU/ml to designate a
positive culture (Table 1). Bronchoscopy - necessary to
perform BAL- is invasive and requires specialised skills.
All culture-based methods may require up to 48 hours
for microbial identification: while waiting for microbiol-
ogy results a broad spectrum antibiotic therapy has to
be started. Causative agent may be the most various:
Staphylococcus aureus, Pseudomonas aeruginosa and
Enterobacteriaceae represent the most frequent patho-
gens in VAP [21,22]. As a result of the overuse of broad-
spectrum antimicrobials such as the carbapenems, strains
of Acinetobacter, Enterobacteriaceae, and Pseudomonas
Table 1 CDC Algorithm for VAP diagnosis [1]
1= Purulent respiratory secretions AND one of the following: 2= One of the following (without requirement for purulent
respiratory secretions):
• Positive culture of endotracheal aspirate, ≥ 105 CFU/ml * • Positive pleural fluid culture
• Positive culture of bronchoalveolar lavage, ≥ 104 CFU/ml* • Positive lung histopathology
• Positive culture of lung tissue, ≥ 104 CFU/ml* • Positive diagnostic test for Legionella spp.
• Positive culture of protected specimen brush, ≥ 103 CFU/ml* • Positive diagnostic test on respiratory secretions for influenza virus,
respiratory syncytial virus, adenovirus, parainfluenza virus
On or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after the onset of worsening oxygenation, criteria 1 or 2 is met
(*or equivalent semi-quantitative result).
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have emerged as important causes of VAP [23]. Definition
of VAP implies that the patient has been intubated (or has
a tracheostomy) for more than 48 hours. A further differ-
entiation can be made, considering the time of onset:
within 96 hours from intubation (early onset VAP) or after
96 hours of intubation (late onset VAP). This differenti-
ation is important to discriminate the potential causative
pathogens, since the late onset VAP is very frequently due
to multi-drug resistant (MDR) agents. The clinician will
start therapy using broad-spectrum antibiotics and stop it
if the diagnosis of infection becomes unlikely. The need to
accurately diagnose VAP so that appropriate discontinu-
ation or de-escalation of antimicrobial therapy can be initi-
ated (to reduce the antimicrobial pressure) is evidently
essential. The second step is then using narrower spectrum
antibiotics, once the etiologic agent is identified, taking into
consideration the pharmacokinetic and pharmacodynamic
properties of the agent selected. Provided that initial ther-
apy was appropriate, the clinical course appears favourable,
and microbiologic data do not point to a very difficult-to-
treat microorganism, the physician could switch to mono-
therapy on days 3–5. But, what if the initial therapy is not
appropriate or if a therapy is started but is inefficacious
against drug resistant bacteria?
A clear example comes from the difficult management
of VAP caused by Acinetobacter baumannii, a resilient
Gram-negative cocco-bacillus, responsible of serious noso-
comial infection, among which is included VAP [24].
Transmission of A. baumannii in association with contam-
ination of hospital equipment or cross-transmission among
patients is easy and common. This spread is linked to the
capacity of bacteria to survive in dry environments and
their need for simple growth conditions and to withstand
disinfection and to persist in the hospital environment.
A. baumannii shows a broad spectrum of resistance to
antimicrobial agents: carbapenems have been reported
as the most appropriate choice for the treatment, but
in A. baumannii resistance to carbapenems may be con-
ferred by some carbapenemases (metalloenzymes) that
hydrolyze imipenem and meropenem. In case of CRAB
(carbapenem-resistant A. baumannii), colistin is the drugof choice to cure the infection even if it has severe
collateral effects and a large rate of failures [25]. Then,
A. Baumanni infections need to be rapidly identified, in
order to treat the pathogens and cure the patients but
also limit the spread, which can cause a micro-epidemic
within the ICU. Nevertheless, resistant A. baumannii
needs to be promptly isolated and the resistant strains
have to be identified to allow the use of colistin or com-
bination of drugs since the first day of VAP diagnosis,
not waiting for the time (3–4 days, depending on the in-
stitution) necessary for obtaining the results of culture
and sensitivity. The importance to start the correct regi-
men immediately is evident in a serious and potentially
epidemic disease as VAP caused by MDR organism but
the clinical routine has not yet the tools to get simplifica-
tion of the causative diagnosis. Promising new techniques
and the application of translational methods to daily
practice may overcome some difficulties. Real-time PCR,
hybridization and mass spectrometry-based platforms are
methods providing quantitative results, which can sup-
port organism identification and detect bacterial resist-
ance directly from clinical specimens [26].
Quantitative polymerase chain reaction (qPCR) i.e.
may reduce the time for microbiological diagnosis,
allowing to start immediately the right antibiotics and
avoiding unnecessary overtreatment. Kwon et al. tried
qPCR for etiologic diagnosis of Methicillin-Resistant
Staphylococcus aureus (MRSA) pneumonia on bronchoal-
veolar lavage or bronchial washing samples [27]. Molecular
identification of MRSA was based on the presence of the
mecA and femA-SA gene, with the absence of the femA-
SE gene. The sensitivity and specificity of this assay were
88.9% and 88.9% respectively (compared with quantitative
cultures). Applying this assay to BAL analysis certainly
improves the diagnosis but it does not avoid the use of
invasive technique as bronchoscopy. To identify pathogen-
derived volatile biomarkers in breath would be a non- inva-
sive method to diagnose VAP. Filipiak et al. made in vitro
experiments with Staphylococcus aureus and Pseudo-
monas aeruginosa (bacteria most frequently found in VAP
patients) to investigate the release or consumption of
volatile organic compounds by gas chromatography mass
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“the detection and perhaps even identification of bac-
teria could be achieved by determination of characteris-
tic volatile metabolites, supporting the clinical use of
breath-gas analysis as a non-invasive method for early
detection of bacterial lung infections” [28]. Chromatog-
raphy for microbiological definition appears as a veryFigure 1 From Mortensen [29] with permission: summary of the dynam
can adhere and invade host cells, leading to stimulation of the pro-inflamm
TLR4 recognition of LPS which then activates MAPK and NF-κB pathways.
receptor proteins leads to subsequent transcription and secretion of pro-inflam
KC/IL-8 and MIP-2. (4) These chemokines recruit granulocytes and lymphocyte
infection host cells also undergo apoptosis. (6) Other host defences include
(7) In response to the host environment, A. baumannii expresses several vir
inset of the figure. The illustration depicts those proteins and molecules tha
expressed. The question marks designate areas in which there are significaninteresting application of a translational technique to
VAP microbiological diagnosis.
Pathogenesis of VAP and its prevention in a genomic
perspective
The relevance of VAP pushed the development of a na-
tional programme in the USA to reduce its incidenceic interplay between A. baumannii and the host. (1) A. baumannii
atory immune response. (2) The inflammatory response is initiated by
TLR2 is also reported to detect A. baumannii. (3) Activation of these
matory mediators such as cytokines IL-6 and TNF-α and chemokines
s that are required for controlling infection. (5) Following A. baumannii
nutritional immunity, ROS/RNS production, and antimicrobial peptides.
ulence factors implicated in pathogenesis, which are displayed in the
t are functionally characterized and those that are predicted to be
t gaps in our knowledge.
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versial (e.g. selective digestive decontamination) till now.
Nevertheless, counteracting the pathogenetic pathways
and limiting the risk factors sounds a reasonable option.
The first measure to reduce VAP is to limit exposure to
mechanical ventilation by preferring non-mechanical ven-
tilation when possible and limiting its duration. Other pre-
vention practices aim at reducing airways colonisation
(such as hygiene before manipulating airways and oral
care decontamination using chlorhexidine), or preventing
aspiration (e.g. by nursing in the semirecumbent position,
or maintaining a sufficient cuff pressure).
Colonisation of the upper airways is probably the main
risk factor for VAP: it is extremely frequent and rapidly
acquired in ICU but not all the colonised patients de-
velop any clinical significant infection, neither all the tra-
cheobronchitis (VAT) become VAP. Normally, bacterial
pathogen-associated molecular patterns (PAMPs) are de-
tected by innate immune receptors on host cells, whose
intracellular signalling pathways promote transcription,Figure 2 From Swanson with permission: hierarchical clustering of VA
expressed genes in patients that went on to develop ventilator-associated p
with the five genes that were common to all sets used in the cross validatioprocessing and secretion of inflammatory mediators [29].
The immune response is principally dependent on how the
host interacts with a given pathogen (Figure 1).
Martin Loaches et al. compared VAP/VAT gene ex-
pression using genome-wide oligonucleotide microarrays
[7]. Comparison of gene expression profiles in the pre-
infection period revealed 5595 genes expressed differen-
tially between VAP and VAT. The Authors reported that
patients who developed VAP had immune impairment
in the pre-infection period, with a lower expression of
genes involved in the complement system, compared to
patients developing simple tracheobronchitis.
Swanson et al. in 10 trauma patients that later devel-
oped VAP, found that gene expression profiles of lipo-
polysaccharide stimulated blood cells were different
from those expressed in controls who did not develop
VAP and showed 5 genes (PIK3R3, ATP2A1, PI3, ADAM8,
and HCN4) common to all significant gene sets used in
the cross validation tests [30]. After LPS stimulation of
whole blood, the expression of these five genes was downP − and VAP + patients. (A) Hierarchical clustering of 810 differentially
neumonia (blue) and those that did not (red). (B) Hierarchical clustering
n tests.
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Hierarchical clustering using these five genes accurately
categorized 95% of patients and PCA visualization dem-
onstrated two discernable groups, VAP + and VAP −
(Figure 2). Of the five genes identified, three appear to
have a role in host response to infection while HCN4 and
ATP2A1 are not directly linked with infection. The envir-
onment of the immune-compromised host and the contri-
bution of the anti-inflammatory response to controlling
damaging inflammation have important implications to
the pathogenesis that we are beginning to appreciate. Im-
munomodulatory therapeutics in these patients with com-
promised immune status may be a beneficial strategy for
treatment of nosocomial infections.
Review and conclusion
Ventilator Associated Pneumonia (VAP) is one of the
most common nosocomial infections in ICU presenting
with not specific symptoms and clinical signs. Too manyFigure 3 A tentative flow chart to introduce step by step the alternatVAP patients still receive inadequate initial antibiotics
even if it is well known that the incidence of MDR
pathogen infections is on the rise in ICU. VAP is one of
the major sites for emergence of MDR pathogens be-
cause subtherapeutic antibiotic concentrations in the
lung necessitate longer duration of therapy, thereby fa-
voring selection of resistant bacteria. The choice of the
initial empiric antibiotic is challenging; the administra-
tion of “broad spectrum” antibiotics may be the safest
decision but is associated to increased resistance rate
and failure of therapy. Combined antibiotics regimens or
more risky antibiotics as colistin may be the only avail-
able choice i.e. when MDR Acinetobacter spp. is sus-
pected. The most practical solution, at the moment,
seems to reduce the time of empiric therapy at its mini-
mum, starting as soon as possible a short course of fo-
cused antibiotics. A short course of antibiotic treatment
(7–8 days) is effective at successfully clearing the infec-
tion, reducing the duration of antibiotic administration,ives from translational medicine step by step.
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hospital mortality, ventilator days, or hospital length of
stay when compared with a 10-day to 15-day course but
currently, there is not enough data to support further
shortening the duration of antibiotic treatment in pa-
tients with culture proven VAP.
Although our insight has significantly increased over
the past years, a translational approach, with application
of genomics, proteomics and metabolomics methodolo-
gies to this severe clinical problem is required to better
understand the disease and hypothesize new therapeutic
strategies. Translational approach seems to be able to
boost the necessary knowledge of VAP in several ways
(Figure 3). The vast number of measurements that could
becomes available for VAP will require powerful inform-
atics methods for organizing the data. We should look
for deeper interactions among basic science researchers
and clinicians to push on translational approach even in
the newest fields as nutribolomics, which could provide
new insight and possibility for the cure of VAP.
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